Pharmacotherapy for Obesity

Past, Present and Future

Ya Wen Hsu, Da Chen Chu, Po Wen Ku, Tsan Hon Liou, Pesus Chou

研究成果: 雜誌貢獻文章

10 引文 (Scopus)

摘要

The prevalence of obesity has rapidly increased in all industrialized countries in the past few decades, most likely due to dietary and lifestyle changes. Since 1980, the prevalence of obesity has increased threefold or more worldwide. Obesity is associated with a number of diseases and metabolic abnormalities, many of which have high morbidity and mortality rates. These diseases include type 2 diabetes, hypertension, dyslipidemia, coronary heart disease, gallbladder disease, and some cancers. Even relatively modest decreases in body-weight (5-10% of the initial body weight) lead to marked improvements in blood pressure, and sugar and lipid control in obese patients. Obesity treatment should begin with lifestyle changes that focus on behavioral modifications, diet control, and regular exercise. Pharmacotherapy provides an adjunct for obesity treatment, but should be used in conjunction with non-pharmacological approaches such as reduced caloric intake and increased exercise. The history of pharmacotherapy for obesity is no great success story because most anti-obesity drugs have been withdrawn from the market based on the US Food and Drug Administration warnings of serious adverse reactions. At present, only orlistat and sibutramine have been approved by the US Food and Drug Administration for long-term use, but sibutramine was withdrawn from sale in the European Union in January 2010. Rimonabant was approved for use in the European Union in 2006 but officially withdrawn in 2009. There are still many compounds under clinical development, including a new cannabinoid-1 receptor antagonist, a 5-HT2c receptor agonist, ghrelin receptor antagonists, and inhibitors of gastrointestinal lipases. All of these compounds are still in preclinical or early clinical development stages. It will take time to tell whether these compounds can be used as anti-obesity drugs in the near future.

原文英語
頁(從 - 到)118-123
頁數6
期刊Journal of Experimental and Clinical Medicine(Taiwan)
2
發行號3
DOIs
出版狀態已發佈 - 六月 2010

指紋

sibutramine
Obesity
Drug Therapy
Anti-Obesity Agents
rimonabant
European Union
United States Food and Drug Administration
Life Style
Ghrelin Receptor
Cannabinoid Receptor Antagonists
Exercise
Gallbladder Diseases
Diet Therapy
Metabolic Diseases
Dyslipidemias
Energy Intake
Lipase
Developed Countries
Type 2 Diabetes Mellitus
Coronary Disease

ASJC Scopus subject areas

  • Medicine(all)

引用此文

Pharmacotherapy for Obesity : Past, Present and Future. / Hsu, Ya Wen; Chu, Da Chen; Ku, Po Wen; Liou, Tsan Hon; Chou, Pesus.

於: Journal of Experimental and Clinical Medicine(Taiwan), 卷 2, 編號 3, 06.2010, p. 118-123.

研究成果: 雜誌貢獻文章

Hsu, Ya Wen ; Chu, Da Chen ; Ku, Po Wen ; Liou, Tsan Hon ; Chou, Pesus. / Pharmacotherapy for Obesity : Past, Present and Future. 於: Journal of Experimental and Clinical Medicine(Taiwan). 2010 ; 卷 2, 編號 3. 頁 118-123.
@article{2c8e85b2a53f4f3d8eec53cd303554ea,
title = "Pharmacotherapy for Obesity: Past, Present and Future",
abstract = "The prevalence of obesity has rapidly increased in all industrialized countries in the past few decades, most likely due to dietary and lifestyle changes. Since 1980, the prevalence of obesity has increased threefold or more worldwide. Obesity is associated with a number of diseases and metabolic abnormalities, many of which have high morbidity and mortality rates. These diseases include type 2 diabetes, hypertension, dyslipidemia, coronary heart disease, gallbladder disease, and some cancers. Even relatively modest decreases in body-weight (5-10{\%} of the initial body weight) lead to marked improvements in blood pressure, and sugar and lipid control in obese patients. Obesity treatment should begin with lifestyle changes that focus on behavioral modifications, diet control, and regular exercise. Pharmacotherapy provides an adjunct for obesity treatment, but should be used in conjunction with non-pharmacological approaches such as reduced caloric intake and increased exercise. The history of pharmacotherapy for obesity is no great success story because most anti-obesity drugs have been withdrawn from the market based on the US Food and Drug Administration warnings of serious adverse reactions. At present, only orlistat and sibutramine have been approved by the US Food and Drug Administration for long-term use, but sibutramine was withdrawn from sale in the European Union in January 2010. Rimonabant was approved for use in the European Union in 2006 but officially withdrawn in 2009. There are still many compounds under clinical development, including a new cannabinoid-1 receptor antagonist, a 5-HT2c receptor agonist, ghrelin receptor antagonists, and inhibitors of gastrointestinal lipases. All of these compounds are still in preclinical or early clinical development stages. It will take time to tell whether these compounds can be used as anti-obesity drugs in the near future.",
keywords = "Orlistat, Overweight, Rimonabant, Sibutramine",
author = "Hsu, {Ya Wen} and Chu, {Da Chen} and Ku, {Po Wen} and Liou, {Tsan Hon} and Pesus Chou",
year = "2010",
month = "6",
doi = "10.1016/S1878-3317(10)60019-8",
language = "English",
volume = "2",
pages = "118--123",
journal = "Journal of Experimental and Clinical Medicine",
issn = "1878-3317",
publisher = "Elsevier Taiwan LLC",
number = "3",

}

TY - JOUR

T1 - Pharmacotherapy for Obesity

T2 - Past, Present and Future

AU - Hsu, Ya Wen

AU - Chu, Da Chen

AU - Ku, Po Wen

AU - Liou, Tsan Hon

AU - Chou, Pesus

PY - 2010/6

Y1 - 2010/6

N2 - The prevalence of obesity has rapidly increased in all industrialized countries in the past few decades, most likely due to dietary and lifestyle changes. Since 1980, the prevalence of obesity has increased threefold or more worldwide. Obesity is associated with a number of diseases and metabolic abnormalities, many of which have high morbidity and mortality rates. These diseases include type 2 diabetes, hypertension, dyslipidemia, coronary heart disease, gallbladder disease, and some cancers. Even relatively modest decreases in body-weight (5-10% of the initial body weight) lead to marked improvements in blood pressure, and sugar and lipid control in obese patients. Obesity treatment should begin with lifestyle changes that focus on behavioral modifications, diet control, and regular exercise. Pharmacotherapy provides an adjunct for obesity treatment, but should be used in conjunction with non-pharmacological approaches such as reduced caloric intake and increased exercise. The history of pharmacotherapy for obesity is no great success story because most anti-obesity drugs have been withdrawn from the market based on the US Food and Drug Administration warnings of serious adverse reactions. At present, only orlistat and sibutramine have been approved by the US Food and Drug Administration for long-term use, but sibutramine was withdrawn from sale in the European Union in January 2010. Rimonabant was approved for use in the European Union in 2006 but officially withdrawn in 2009. There are still many compounds under clinical development, including a new cannabinoid-1 receptor antagonist, a 5-HT2c receptor agonist, ghrelin receptor antagonists, and inhibitors of gastrointestinal lipases. All of these compounds are still in preclinical or early clinical development stages. It will take time to tell whether these compounds can be used as anti-obesity drugs in the near future.

AB - The prevalence of obesity has rapidly increased in all industrialized countries in the past few decades, most likely due to dietary and lifestyle changes. Since 1980, the prevalence of obesity has increased threefold or more worldwide. Obesity is associated with a number of diseases and metabolic abnormalities, many of which have high morbidity and mortality rates. These diseases include type 2 diabetes, hypertension, dyslipidemia, coronary heart disease, gallbladder disease, and some cancers. Even relatively modest decreases in body-weight (5-10% of the initial body weight) lead to marked improvements in blood pressure, and sugar and lipid control in obese patients. Obesity treatment should begin with lifestyle changes that focus on behavioral modifications, diet control, and regular exercise. Pharmacotherapy provides an adjunct for obesity treatment, but should be used in conjunction with non-pharmacological approaches such as reduced caloric intake and increased exercise. The history of pharmacotherapy for obesity is no great success story because most anti-obesity drugs have been withdrawn from the market based on the US Food and Drug Administration warnings of serious adverse reactions. At present, only orlistat and sibutramine have been approved by the US Food and Drug Administration for long-term use, but sibutramine was withdrawn from sale in the European Union in January 2010. Rimonabant was approved for use in the European Union in 2006 but officially withdrawn in 2009. There are still many compounds under clinical development, including a new cannabinoid-1 receptor antagonist, a 5-HT2c receptor agonist, ghrelin receptor antagonists, and inhibitors of gastrointestinal lipases. All of these compounds are still in preclinical or early clinical development stages. It will take time to tell whether these compounds can be used as anti-obesity drugs in the near future.

KW - Orlistat

KW - Overweight

KW - Rimonabant

KW - Sibutramine

UR - http://www.scopus.com/inward/record.url?scp=77953891130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953891130&partnerID=8YFLogxK

U2 - 10.1016/S1878-3317(10)60019-8

DO - 10.1016/S1878-3317(10)60019-8

M3 - Article

VL - 2

SP - 118

EP - 123

JO - Journal of Experimental and Clinical Medicine

JF - Journal of Experimental and Clinical Medicine

SN - 1878-3317

IS - 3

ER -